ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 40

Inflammation and Neuronal Growth Factors in Rheumatoid Arthritis

Caroline Wasén1, Lovisa Leifsdottir 2, Roda Abdalla 1, Lina Juzokaite 1, Karin Andersson 1, Malin Erlandsson 1, Marie Kalm 3 and Maria Bokarewa 1, 1Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden, 2Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gotheburg, Sweden, 3hDepartment of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: inflammation and Cell Signaling, neuropsychiatric disorders, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Etiology & Pathogenesis Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Depression and cognitive impairment are frequently reported in rheumatoid arthritis (RA). We have recently presented that reduced hippocampus volume may be linked to functional disability and enhanced pain response in patients with RA (Andersson and Wasén et al. 2018). Reduced hippocampus volume and reduced neurogenesis (in hippocampus) was suggested related to insulin-like growth-factor 1 (IGF1) signaling in both RA patients and experimental models. Here, we aim to investigate the relation between growth factors of importance for neuronal growth and inflammation in RA and experimental arthritis.

Methods: Serum of 254 RA patients was analyzed for inflammatory markers IL-1b and IL-6 in addition to growth factors IGF1, brain-derived neurotrophic factor (BNDF) and vascular endothelial growth-factor (VEGF) and compared to the patients’ disease activity (DAS28). Mice with collagen-induced arthritis were treated with short hairpin (sh)RNA targeting expression of IGF1 receptor (IGF1R). IBA1+ (microglia), DCX+ (developing neurons) and serin256-phosphorylated FoxO1+ (target of IGF1 signaling) cells in the hippocampal structures dentate gyrus (DG) and cornu ammonis (CA1-3) were identified by immunohistochemistry.

Results: Serum levels of IGF1, BNDF and VEGF all had weak but significant correlations to IL-1b (r= 0.12, 0.20 and 0.19, p= 0.049, 0.0013 and 0.0032, respectively). IGF1 was inversely correlated to IL-6 levels (r= -0.15, p= 0.020) and BNDF was negatively associated with disease activity (r= -0.14, p= 0.038). High serum IGF1 was associated with less expression of IGF1R in human peripheral blood monocytes (r= 0.25 p= 0.023). In IGF1R inhibited mice, the density of IBA1+ microglial cells was decreased in DG and CA regions of the hippocampus, indicating reduced local inflammation. The density of pFoxO1+ cells was increased in DG (p=0.0046) and CA3 (p=0.0030) when IGF1R was inhibited. The density of pFoxO1+ cells in DG and CA3 was positively correlated with serum IGF1 (r= 0.64 and 0.51, p= 0.0006 and 0.0080). However, the density of pFoxO1+ cells in DG and CA3 was negatively correlated with the number of DCX+ developing neurons (r= -0.46 and -0.65, p= 0.078 and 0.014).

Conclusion: We conclude that systemic inflammation measured as higher disease activity and IL-6 levels were associated with low BNDF, while serum IL-1b may stimulate release of growth factors IGF1, BNDF and VEGF into serum. Inhibition of IGF1R resulted in increased serum levels of IGF1, increased FoxO1 phosphorylation in the hippocampus, but this appeared to be insufficient to rescue neurogenesis.


Disclosure: C. Wasén, None; L. Leifsdottir, None; R. Abdalla, None; L. Juzokaite, None; K. Andersson, None; M. Erlandsson, None; M. Kalm, None; M. Bokarewa, None.

To cite this abstract in AMA style:

Wasén C, Leifsdottir L, Abdalla R, Juzokaite L, Andersson K, Erlandsson M, Kalm M, Bokarewa M. Inflammation and Neuronal Growth Factors in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/inflammation-and-neuronal-growth-factors-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammation-and-neuronal-growth-factors-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology